FDA Requests Removal of Ranitidine (Zantac)

The U.S. Food and Drug Administration has announced that all prescription and over-the-counter ranitidine (Zantac) drugs should be removed from the market immediately. The FDA is advising consumers stop taking OTC ranitidine (tablets or liquid) and dispose of them as soon as possible. The push to fully remove this drug from the market is part of an on-going investigation by the FDA of a contaminant known as NDMA, a probable human carcinogen.

Zantac, the most commonly sold brand name of ranitidine, already began removing their product from shelves in September of 2019. This decision came after the FDA first requested the voluntary recall of many ranitidine products after third party laboratory testing found high levels of NDMA present. Small levels of NDMA are commonly found in your average diet. Small amounts of NDMA are safe to consume and the FDA has set the acceptable daily intake limit for NDMA at 0.096 micrograms. Testing found that levels in Zantac could exceed this limit significantly when the medication is kept at a high temperature for an extended period of time.

NDMA is classified as a B2 carcinogen, meaning higher levels of exposure (like those found in Zantac) can increase the risk of cancer found within the digestive system (esophagus, stomach, colon, etc.) and is extremely toxic to the liver.

If you or a loved one have suffered side effects from taking Zantac please contact us today. Forester Haynie is currently investigating potential Zantac lawsuits on behalf of those who have been negatively impacted by the drug.

Fill out our form below if you think you have a case:

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *